STERIS plc

• Valuation4.5 / 10
• Management8.5 / 10
• Balance Sheet8 / 10
• Profitability5.5 / 10
• Revenue Growth6 / 10
• Risk Assessment7.5 / 10
• Competitive Moat9 / 10
• Earnings Quality8 / 10
• Capital Efficiency5.5 / 10

STERIS operates an advantaged business model characterized by mission-critical regulatory barriers and high recurring cash flows. In acute care hospitals and ambulatory surgery centers, its installed base of automated endoscope reprocessors and sterilizers drives continuous pull-through of dedicated chemistries and consumables,. In outsourced contract sterilization, strict regulatory validations make customer substitution virtually impossible, cementing long-term biopharmaceutical relationships.^4,7

At the report-date share price of $214.40 as of October 9, 2026, STERIS trades at a 2.31% premium to its fundamental Fair value of $209.55 (representing an implied return of -2.26%). The company is actively investing ~$450M in FY2027 capital expenditures to consolidate operations into an automated greenfield facility in North Carolina,. While this project expands long-term capacity, near-term free cash flow is temporarily constrained and customer destocking in AST continues to weigh on first-half volumes.^3,4

We conclude that while STERIS is an exceptional compounder with an ROIC of 9.33% outpacing its 8.60% WACC, the current valuation adequately reflects its near-term earnings power. Investors should hold existing allocations and wait for a wider margin of safety before deploying new capital.¹

The downside scenario reflects the compounding impact of acute care hospital capital spending freezes and prolonged biopharmaceutical inventory destocking. Under this path, high-margin capital equipment installations stall, contract sterilization volumes experience fixed cost under-absorption, and persistent import tariffs erode operating profitability without the benefit of timely price realization.

Healthcare capital equipment revenue grew only 1% in Q1 FY2027 due to timing of shipments. If acute care hospitals institute capital equipment freezes due to macroeconomic reimbursement pressure, capital sales turn negative, reducing consolidated revenue growth by 5 percentage points across the 5-year forecast horizon.^4,7

Indicates biopharma customer destocking has extended into structural volume loss and existing facility capacity limits have bound before North Carolina ramps, triggering fixed cost under-absorption.

現在:Tamped down in H1 FY2027 by comparisons and destocking; guided to 7%-8% for full year,

Under the bull case, with probability 20.0% and target $249.66 yielding an implied return of 16.4%, customer inventory destocking in contract sterilization resolves ahead of schedule while automated endoscope reprocessor share gains accelerate. Operating margins expand beyond historical peaks as the automated North Carolina facility ramps, driving double-digit operational earnings growth.

High-margin proprietary chemistries and single-use consumables create an annuity stream that expands segment operating margins and insulates cash flow.

Forecast cash flows / share

$31.37

Terminal value / share

$119

Signed net debt / current share

$14.08